JP2007514769A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514769A5
JP2007514769A5 JP2006545566A JP2006545566A JP2007514769A5 JP 2007514769 A5 JP2007514769 A5 JP 2007514769A5 JP 2006545566 A JP2006545566 A JP 2006545566A JP 2006545566 A JP2006545566 A JP 2006545566A JP 2007514769 A5 JP2007514769 A5 JP 2007514769A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
medical condition
heart disease
angina
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006545566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/042859 external-priority patent/WO2005061470A1/en
Publication of JP2007514769A publication Critical patent/JP2007514769A/ja
Publication of JP2007514769A5 publication Critical patent/JP2007514769A5/ja
Pending legal-status Critical Current

Links

JP2006545566A 2003-12-18 2004-12-17 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物 Pending JP2007514769A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53125303P 2003-12-18 2003-12-18
PCT/US2004/042859 WO2005061470A1 (en) 2003-12-18 2004-12-17 1-akan-2-ol substituted piperazine and piperidine compounds

Publications (2)

Publication Number Publication Date
JP2007514769A JP2007514769A (ja) 2007-06-07
JP2007514769A5 true JP2007514769A5 (cg-RX-API-DMAC7.html) 2008-01-24

Family

ID=34710215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006545566A Pending JP2007514769A (ja) 2003-12-18 2004-12-17 1−アルカン−2−オール置換ピペラジンおよびピペリジン化合物

Country Status (7)

Country Link
US (4) US7115610B2 (cg-RX-API-DMAC7.html)
EP (1) EP1723129A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007514769A (cg-RX-API-DMAC7.html)
KR (1) KR20060124646A (cg-RX-API-DMAC7.html)
AU (1) AU2004303882A1 (cg-RX-API-DMAC7.html)
CA (1) CA2550257A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005061470A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
EP1829866A1 (en) * 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
BRPI0913291A2 (pt) 2008-05-30 2019-01-15 Takeda Pharmaceuticals Co composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
CN105175401A (zh) * 2015-10-16 2015-12-23 北京康立生医药技术开发有限公司 一种依匹哌唑的制备方法
EP4334293A1 (en) * 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2034305B (en) * 1978-10-24 1982-12-22 Wyeth John & Brother Ltd Preparation of piperidine derivatives
DE3118881A1 (de) 1980-09-29 1982-06-24 Oltmanns Ziegel Und Kunststoffe Gmbh, 2905 Edewecht "ziegel"
US4766125A (en) 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4558129A (en) 1983-05-18 1985-12-10 Syntex (U.S.A.) Inc. Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
ES2177601T3 (es) 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
HU209723B (en) * 1990-10-31 1994-10-28 Richter Gedeon Vegyeszet Process for producing of piperazine derivatives
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
NZ520780A (en) * 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001238590A1 (en) 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
NZ520782A (en) * 2000-02-22 2004-03-26 Cv Therapeutics Inc Substituted piperazine compounds that are partial fatty acid oxidation inhibitors
US6451798B2 (en) 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
IL151626A0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
MXPA04000565A (es) * 2001-07-19 2005-06-17 Cv Therapeutics Inc Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos.
US7001909B2 (en) 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
JP4171425B2 (ja) * 2002-03-05 2008-10-22 チバ ホールディング インコーポレーテッド カラー写真記録材料
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds

Similar Documents

Publication Publication Date Title
JP2006526031A5 (cg-RX-API-DMAC7.html)
NZ716245A (en) Fused benzoxazepinones as ion channel modulators
JP2008506632A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2023534131A5 (cg-RX-API-DMAC7.html)
JP2006519232A5 (cg-RX-API-DMAC7.html)
JP2005508905A5 (cg-RX-API-DMAC7.html)
JP2010501534A5 (cg-RX-API-DMAC7.html)
JP2007522220A5 (cg-RX-API-DMAC7.html)
JP2010504908A5 (cg-RX-API-DMAC7.html)
DK1370530T3 (da) Acyleret 1,2,3,4-tetrahydronaphtylaminer og anvendelse deraf som farmaceutisk produkt
NO20032765D0 (no) Terapeutisk forening av amlodipin og benazepril/benazeprilat
NO20040234L (no) Substituerte piperazinforbindelser og anvendelse av disse som inhibitorer for oksydasjon av fettsyrer
JP2008513510A5 (cg-RX-API-DMAC7.html)
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
JP2007521013A5 (cg-RX-API-DMAC7.html)
JP2006525972A5 (cg-RX-API-DMAC7.html)
JP2009055850A5 (cg-RX-API-DMAC7.html)
JP2006298895A5 (cg-RX-API-DMAC7.html)
CA2400176A1 (en) Substituted piperazine compounds
NO20070147L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
JP2004517961A5 (cg-RX-API-DMAC7.html)
JP2008505852A5 (cg-RX-API-DMAC7.html)
JP2005029789A5 (cg-RX-API-DMAC7.html)
ATE443058T1 (de) Substituierte heterozyklische verbindungen